Gbrain

Gbrain operates at the intersection of neurotechnology, medical devices, biotechnology, and clinical research. Its differentiation is a vertically integrated offering: the company develops graphene-based and penetrating electrode arrays, supplies wired and wireless neural data acquisition systems, and offers contracted development and manufacturing for clinical-grade devices. The portfolio spans animal research through potential human applications, with channel counts ranging from four to 1,024 and support for models ranging from small animals to non-human primates. This breadth gives Gbrain a broader commercialization pathway than a company focused only on a single implant or software layer. The company’s patent activity in 2022 and 2023 further supports a focus on wireless neural interfaces and implantable measurement and stimulation structures. Relative to those internationally recognized BCI developers, Gbrain appears to have a more research-tools and component-oriented profile, with graphene electrodes and custom manufacturing as central differentiators.

The company was founded on Aug 15, 2019 and completed a single Pre Seed round on May 1, 2020 backed by Innopolis Partners and TIPS Program. The funding amount is undisclosed, and there is no documented later financing, valuation, hiring trend, or workforce expansion beyond an estimated employee band of 11 to 50 people. Product development has broadened across several layers of the neurotechnology stack: graphene sheets and cortical electrode arrays provide the materials and sensing interface; wired and wireless acquisition systems provide data collection; and contracted development and manufacturing services support external or clinical-device programs. Patent publications on Dec 27, 2022 and Feb 8, 2023 mark identifiable technical inflection points in wireless neural interfaces and injectable brain signal measurement and stimulation structures. Six granted patents and two registered trademarks provide additional evidence of ongoing intellectual-property development. Gbrain appears to be advancing technically, but its growth rate and market conversion remain difficult to quantify.